Theagene Jean-Manasse bought MAIA
June 30, 2026 · Form 4 insider transaction
Theagene Jean-Manasse bought 26,355 shares of MAIA Biotechnology, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
26,355
Price
$0.00
Total value
N/A
InsiderTheagene Jean-Manasse
Role—
SecurityStock Options
Transaction codeA: Grant or award
Transaction dateJune 30, 2026
Filing dateJuly 2, 2026
Shares owned after26,355
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.